Developments in Antiviral Drug Design, Discovery and Development in 2004

Author(s): Nicholas A. Meanwell, Makonen Belema, David J. Carini, Stanley V. D'Andrea, John F. Kadow, Mark Krystal, B. N. Naidu, Alicia Regueiro-Ren, Paul M. Scola, Sing-Yuen Sit, Michael A. Walker, Tao Wang, Kap-Sun Yeung.

Journal Name: Current Drug Targets - Infectious Disorders
Continued as Infectious Disorders - Drug Targets

Volume 5 , Issue 4 , 2005


This article summarizes key aspects of progress made during 2004 toward the design, discovery and development of antiviral agents for clinical use. Important developments in the identification, characterization and clinical utility of inhibitors of human immunodeficiency virus; the hepatitis viruses, hepatitis B, hepatitis C; the herpes family of viruses, herpes simplex viruses 1 and 2, varicella zoster virus, Epstein-Barr virus and human cytomegalovirus; the respiratory viruses, influenza, respiratory syncytial virus, human metapneumovirus, picornaviruses, measles and the severe acute respiratory syndrome coronavirus; human papilloma virus; rotavirus; Ebola virus and West Nile virus, are reviewed.

Keywords: HIV Drugs, Mother-to-child transmission (MTCT), HIV resistance, Microbicide, co-receptor antagonist, Immunization

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Page: [307 - 400]
Pages: 94
DOI: 10.2174/156800505774912893
Price: $58

Article Metrics

PDF: 3